Horizon Will Submit Krystexxa sBLA To Strengthen Clinical Profile In Gout
A clinical trial confimred Krystexxa in combination with methotrexate increased response rates in patients with uncontrolled gout.
You may also be interested in...
Now that Amgen has completed its $27.8bn acquisition of Horizon, the company can focus on how it will turn Tepezza back into a growth product and maintain momentum for Krystexxa and other assets.
Sales of the thyroid eye disease drug were impacted by surging COVID-19 case numbers in the first quarter, but the company is expanding its commercial team to capitalize on new TED market insights.
The rare disease specialist held its first R&D day since acquiring Viela Bio and laid out the development strategy for four mid-stage drugs to drive long-term growth.